EXO1 and breast cancer: In contrast, no effect of Exo1 targeting was observed when we transfected siExo1 in the newly generated BRCA2-proficient p53−/− mammary tumor cells with a homozygous Parg frameshift mutation (KP-P1) (Figs. 2C and EV2H–J).